About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
Medicine still has many challenges to solve specially on complex diseases were a large number of both, genetic and environmental factors are involved. Among them, neurodegenerative and autoimmune disorders affecting the central nervous system have attracted attention because CNS is difficult to access and to manipulate with classical pharmacological treatments and, in addition, there are no effective curative treatments for these diseases. To address these problems, we have focused our research interests in gene therapy strategies for autoimmune diseases and neurodegenerative disorders specially those associated to aging.
IP: Miguel Chillon Rodriguez Collaborators: - Funding agency: Instituto de Salud Carlos III Funding: 169097.5 Reference: AC20/00051 Duration: 01/01/2021 - 31/10/2024
PMID: 33572045 Journal: Nutrients Year: 2021 Reference: Nutrients. 2021 Feb 9;13(2). pii: nu13020562. doi: 10.3390/nu13020562. Impact factor: 5.719 Publication type: Paper in international publication Authors: Vogel-Gonzalez, Marina, Tallo-Parra, Marc, Herrera-Fernandez, Victor, Perez-Vilaro, Gemma, Chillon, Miguel, Nogues, Xavier, Gomez-Zorrilla, Silvia, Lopez-Montesinos, Inmaculada, Arnau-Barres, Isabel, Sorli-Redo, Maria Luisa et al. DOI: 10.3390/nu13020562
PMID: 25410741 Journal: GENE THERAPY Year: 2015 Reference: Gene Ther. 2015 Feb;22(2):196-201. doi: 10.1038/gt.2014.103. Epub 2014 Nov 20. Impact factor: 3.104 Publication type: Paper in international publication Authors: Thwaite, R, Pages, G, Chillon, M, Bosch, A et al. DOI: 10.1038/gt.2014.103
PMID: 24132489 Journal: Methods in molecular biology (Clifton, N.J.) Year: 2014 Reference: Methods Mol Biol. 2014;1089:231-43. doi: 10.1007/978-1-62703-679-5_16. Impact factor: 0 Publication type: Paper in international publication Authors: Miralles, Marta, Garcia, Marc, Tejero, Marcos, Bosch, Assumpcio, Chillon, Miguel et al. DOI: 10.1007/978-1-62703-679-5_16
PMID: 24132485 Journal: Methods in molecular biology (Clifton, N.J.) Year: 2014 Reference: Methods Mol Biol. 2014;1089:159-73. doi: 10.1007/978-1-62703-679-5_12. Impact factor: 0 Publication type: Paper in international publication Authors: Penalva, Cristina, Monfar, Merce, Chillon, Miguel, Piedra, Jose, Ontiveros, Maria, Miravet, Susana et al. DOI: 10.1007/978-1-62703-679-5_12
PMID: 24369061 Journal: CURRENT GENE THERAPY Year: 2013 Reference: Curr Gene Ther. 2013 Oct;13(5):370-81. Impact factor: 5.318 Publication type: Review in national publication Authors: Cots, Dan, Bosch, Assumpcio, Chillon, Miguel et al. DOI:
This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.
Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.
Check the current rates for the services offered by the Gene Therapy at Nervous System research group.
